Celebrating the 10th Anniversary:
A Message from Our Editors-in-Chief
We could not be prouder of all that Cancer Immunology Research achieved in its first 10 years (2013-2023) or be more grateful to the community for its support of the Journal during that time. In our 10th anniversary editorial and an accompanying interview, we discussed the Journal's origins, how the Journal’s growth mirrored that of the field of cancer immunology, and the immense potential that we see for future advances in this rich and vibrant field.
A conversation with Editors-in-Chief Philip D Greenberg, MD and Robert D. Schreiber, PhD
There's no question that there's clinical applications now of cancer immunology, but that all of them are built on basic science studies and understanding how the immune system can interact with cancer.
RESEARCH
Top Ten for Ten Years of Cancer Immunology Research
Read our collection of the most-cited research articles, based on citation rate from date of publication to January 2023, for each of the 10 years of Cancer Immunology Research's publication. Congratulations to the authors of these outstanding articles!
The therapeutic potential of CTLA-4 blockade is evident in the ability of anti-CTLA-4 antibody to induce regression of established tumors. In an elegant set of experiments using a panel of murine immunoglobulin in various isotypes, Selby and colleagues delineated the mechanism of action of CTLA-4 blockade. Anti-CTLA-4 promotes antitumor activity by a selective reduction of intratumoral T-regulatory cells along with concomitant activation of T-effector cells.
Using tissue microarrays containing 105 triplenegative breast cancer (TNBC) specimens, Mittendorf and colleagues show that 20% of the TNBC specimens express PD-L1, half have lost PTEN, and inhibitors of PI3K pathway decrease PD-L1 expression, providing a rationale for therapeutic targeting of PD-L1 for TNBC.
Sharabi and colleagues show in two mouse tumor models that radiotherapy combined with D-1 blockade or Treg depletion improves local tumor control by increasing antigen-experienced and effector-memory T cells, antigenMHC complexes, and T-cell infiltration into tumors via antigen cross-presentation in the tumor-draining lymph node.
Bispecific chimeric antigen receptors (CARs) have been systematically optimized to simultaneously target two clinically relevant antigens, CD19 and CD20, presenting a clinically applicable solution to antigen escape and facilitating the rational design of receptors with higher-level complexities.
A meta-analysis of immune checkpoint therapies showed a small but significant increase in the risk of developing key immune-related adverse events of any grade, as well as selected high-grade gastrointestinal and liver toxicities.
Treatment interruption due to irAEs in NSCLC patients treated with anti-PD-L1 was retrospectively assessed. Data suggest that treatment discontinuation should be considered for patients requiring hospitalization for irAEs and those with objective responses prior to irAE onset.
Gastric cancer TME infiltration patterns were determined and systematically correlated with TME cell phenotypes, genomic traits, and patient clinicopathological features to establish the 'TMEscore.' This score was a prognostic and predictive factor for immune checkpoint blockade response.
An approach was developed that utilizes features of CT imaging to identify early responses to immune checkpoint blockade, help predict overall survival, and establish associations with tumor-infiltrating lymphocytes.
Macrophage polarization state, rather than overall density, in the colorectal cancer microenvironment is associated with cancer-specific survival independent of potential confounding factors, with M1-like and M2-like macrophage phenotypes exhibiting distinct prognostic roles.
The authors have established a library of human mutant p53–reactive T-cell receptors potentially useful for the treatment of 7.3% of patients with cancer and show one metastatic breast cancer patient responding to such therapy.
RSS Feeds